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CHAPTER 17
PCR-based methods to determine
DNA methylation status at speciﬁc
CpG sites using methylation-sensitive
restriction enzymes
Helmtrud I. Roach and Ko Hashimoto
In recent years, there has been an explosion of interest in epigenetics, which refers
to heritable changes in gene expression without alteration in the DNA sequence.
The major epigenetic changes are histone acetylation and DNA methylation.
Methylation takes place at cytosines that are adjacent to guanines, the so-called
CpG sites. However, very little information is available on the methylation status
of particular CpG sites in the promoter regions of speciﬁc genes from different cell
types or cells from different developmental stages. This is due to several factors:
1. While DNA sequence analysis can be carried out on DNA extracted from any
cell in the body, the methylation status for a particular gene is cell-type
speciﬁc and thus needs to be analyzed separately for each tissue.
2. As PCR ampliﬁcations eliminate all CpG methylation, it is necessary to obtain
sufﬁcient genomic DNA directly from the relevant tissue/cells rather than by
ampliﬁcation of speciﬁc DNA segments.
3. Although the bisulﬁte modiﬁcation method of detecting the presence or
absence of methylation (see Chapter 16) gives valuable results, it is not best
suited in all instances.
On the whole, conformationally relaxed chromatin (euchromatin) indicates
transcriptionally active regions and is associated with hypomethylated DNA and
acetylated histones, whereas compact chromatin (heterochromatin) is
transcriptionally silent, hypermethylated, and bound to nonacetylated histones.
DNA methylation is thus one of the principal mechanisms by which cells maintain
1. INTRODUCTION
PCR: (S. Hughes and A. Moody, eds.) 
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see (1–6).
2.1 Methylation-sensitive restriction enzymes (MSREs)
The methylation sensitivity of certain restriction enzymes provides an elegant and
straightforward method of assessing methylation status of speciﬁc CpG sites.
There are over 50 such enzymes (see Table 1), all of which have at least one CpG
site within their recognition sequence. However, the cleavage site is not
necessarily within the CpG site or within the recognition sequence, as illustrated
for BceAI below, where the cleavage site is 12 bp downstream from the last base
of the recognition sequence for the top strand and 14 bp upstream for the
complementary strand:
5¢-ACGGCNNNNNNNNNNNNØNN-3¢
3¢-TGCCGNNNNNNNNNNNNNNØ-5¢
2. METHODS AND APPROACHES
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Table 1. Recognition sequences and sites of cleavage of commercially available MRSEs 
In some cases, the cleavage site is some distance away from the recognition site. In this case, the
numbers in parentheses indicate the distance between the last given nucleotide and the cleavage site.
The ﬁrst number is for the 5¢Æ3¢ strand and the second for the complementary strand. W = A or T; Y =
C or T; R = G or A. From: http://rebase.neb.com/rebase/rebase.html.
Enzyme Site Enzyme Site Enzyme Site Enzyme Site
AatII GACGTØC BsmBI CGTCTC (1/5) HaeII RGCGCØY NruIT C G ØCGA
AciIC ØCGC BspDI ATØCGAT HgaI GACGC (5/10) PaeR7I CØTCGAG
AclIA A ØCGTT BspEI TØCCGGA HhaIG C G ØC PmlI CACØGTG
AfeI AGCØGCT BsrBI CCGCTC (-3/-3) HinP1I GØCGC PvuI CGATØCG
AgeIA ØCCGGT BsrFI RØCCGGY HpaII CØCGG RsrII CGØGWCCG
AscIG G ØCGCGCC BssHII GØCGCGC Hpy99I CGWCGØ SacII CCGCØGG
AsiSI GCGATØCGC BstBI TTØCGAA HpyCH4IV AØCGT SalIG ØTCGAC
AvaIC ØYCGRG BstUI CGØCG KasIG ØGCGCC SfoI GGCØGCC
BceAI ACGGC (12/14) ClaIA T ØCGAT MluIA ØCGCGT SgrAI CRØCCGGYG
BmgBI CACØGTC  EagIC ØGGCCG NaeI GCCØGGC SmaI CCCØGGG
BsaAI YACØGTR FauI CCCGC (4/6) NarIG G ØCGCC SnaBI TACØGTA
BsaHI GRØCGYC FseI GGCCGGØCC NgoMIV GØCCGGC TliIC ØTCGAG
BsiEI CGRYØCG FspIT G C ØGCA NotIG C ØGGCCGC XhoIC ØTCGAG
BsiWI CØGTACG
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The principle of this method is illustrated in Fig. 1. If the cytosine of a speciﬁc CpG
site is not methylated, then the enzymes cleave as expected. However, if the
cytosine of the CpG is methylated, then the enzymes cannot cleave and the DNA
remains intact. By designing suitable primer pairs that bracket the region of
interest, the presence or absence of methylation can be determined by the
presence or absence of a PCR band following enzymatic digestion. The MSRE
method is relatively easy and is particularly suitable for promoters with a limited
number of CpG sites and if only small quantities of DNA are available. There are,
however, two points for consideration:
• MSREs might not be available for a speciﬁc CpG site of interest.
• There may be several CpG sites cut by the same MSRE within the PCR-
ampliﬁed region.
The latter is a particular problem for CpG island promoters, where the
concentration of CpGs is very high and will require careful primer design (see
section 2.3). However, if the aim is preliminary scanning of CpGs, for example to
provide ‘proof of concept’ data that a change in methylation has taken place
somewhere, then the MSRE method will provide useful results. 
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Figure 1. Principles of the MRSE assay for methylation status at speciﬁc CpG sites.
In the absence of methylation (left), DNA is cleaved and cannot be ampliﬁed by PCR. In
the presence of methylation (right), the DNA remains intact and can be ampliﬁed with
suitable primer pairs.
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To ﬁnd the promoter region sequence for the gene of interest, we recommend
using the National Center for Biotechnology Information (NCBI) website
(http://www.ncbi.nlm.nih.gov/).
• Select the ‘Gene’ option in the drop-down search box on the left. Type in the
name of the gene of interest and then select the appropriate species from the
list given. Scroll down to the section titled ‘Related sequences’, which, in most
cases, will provide a list of accession numbers for genomic DNA. Clicking 
on the separate accession numbers should identify a ﬁle containing
1000–2000 bp of sequence upstream of the transcription start site, which
corresponds to the promoter. Knowledge of the characteristics of the
promoter will help to identify the most relevant area. If this information is not
available, concentrate initially on the sequence ~1000 bp upstream of exon 1.
• Copy the sequence into Microsoft Word, then use the ‘Find/replace’ facility to
mark all ‘CG’s by replacing them with CG (in bold, larger font and maybe
change the color to red). Do the same for ‘C G’, then scan the right-hand edge
for single Cs and determine whether the next line contains a ‘G’. This will
immediately give you useful information about whether the promoter
contains a CpG island (many closely spaced CpG sites) or is a sparse CpG
promoter.
• To ﬁnd out which MSREs cut your sequence, go to
http://www.restrictionmapper.org/ and select all 53 MSREs (listed in Table 1).
• Paste your sequence of interest into the box in the ‘Sequence Info’ section and
click on ‘Map sites’. This will generate a list of MRSEs that cut within your
sequence and their cut positions. If you have more than one sequence to map,
it is useful to do this straight away, as the program remembers the selected
MSREs. Use the information to map the cut positions onto your sequence. 
• Design PCR primers to bracket the region of interest. Primers should be located
in regions with no CpG sites. An example of a sparse CpG promoter is the
matrix metalloproteinase 13 (MMP-13) gene promoter, shown
diagrammatically in Fig. 2. For this gene, the methylation status has been
determined successfully for six out of the ten CpG sites in a 600 bp promoter
region (7), using unique enzyme/primer combinations. 
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In most studies, the aim is to link DNA methylation status directly to mRNA
expression, for example, to determine whether loss of methylation at a particular
CpG site is associated with induction of gene expression. In this case, simultaneous
extraction of genomic DNA and RNA from the same specimen is highly desirable.
However, in practice, this is not always possible. A particular problem arises if the
tissue contains a lot of extracellular matrix with relatively few cells, as is the case
for adult articular cartilage or muscle ﬁbers. There are many commercially
available kits (e.g. Qiagen) for the extraction of either RNA or DNA. However,
combined kits for simultaneous RNA and DNA extraction are so far only available
as microkits suitable for cells, not for whole tissues.
If DNA (or RNA) is to be extracted directly from whole tissues, a freezer mill is
ideal to grind the tissue under liquid nitrogen into a ﬁne powder (see Protocol 1).
We have successfully used the Spex Certiprep 6750 for grinding human articular
cartilage.
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Figure 2. Example of a promoter suitable for the MSRE assay.
Ten CpG sites, cut by four different enzymes, are present within a 550 bp promoter
region upstream from the transcription start site of MMP-13. Six of these sites (plus one
in the coding region) can be assessed uniquely by various enzyme/primer combinations.
However, four sites cannot be examined, as no MSREs are available to cut at these sites.
The AvaI site at –136 was only evaluated with primers MMP-13b. Hpy, HpyCH4IV.
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Preparation of tissue for DNA or RNA extraction using a
freezer mill
Equipment and Reagents 
■ Freezer mill (Spex Certiprep or similar)
■ 10 ml Sterile tube
■ Small spatula (to scoop out smashed specimen)
■ Weighing scales
Method
1. Work in a well-ventilated room.
2. Pre-cool the freezer mill as instructed by the manufacturer.
3. Pour liquid nitrogen into the freezer milla. Close the lid slowly to avoid spitting of the liquid
nitrogen, as it boils vigorously the ﬁrst time it is poured.
4. Weigh a 10 ml sterile tube. 
5. Transfer samples into freezer mill cylinders with a metal rod, pre-cool, and run the milling
cycles as instructed. Two samples can be pre-cooled while the ﬁrst is being milled.
6. Scoop out the smashed samples and put them into the 10 ml tube using the spatulab. 
7. Reweigh the tube and calculate the milled weight of the sample (100–500 mg is ideal)c. 
8. Add lysis buffer as used in the DNA or RNA extraction kit and store the sample at –20°C or
proceed directly to nucleic acid extraction (see Protocol 2).
9. Wash the cylinders and prepare the next samples.
Notes
aWear a long-sleeved laboratory coat, cryo-resistant gloves, and goggles when handling liquid
nitrogen.
bThe yield of milled powder may be low as some sample inevitably remains inside the cylinder or
attached to the metal rods. If complete recovery of the sample is critical, lysis buffer may be added
directly to the mill cylinders.
cIf both RNA and DNA are to be extracted from the same sample, it is best to split the milled powder
into two and then use a maxi or midi kit for RNA or DNA, respectively. Alternatively, isolate the cells
from the tissue prior to RNA/DNA extraction, as in Protocol 2.
2.4.1 Simultaneous extraction of RNA and DNA from cells
Depending on the tissue, it may be possible to isolate the cells from their matrix
prior to DNA or RNA extraction. This has the advantage that no freezer mill is
required and kits for simultaneous extraction of RNA and DNA can be used (see
Protocol 2).
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Simultaneous extraction of RNA and DNA from cells
Equipment and Reagents
■ AllPrep DNA/RNA mini kit (Qiagen)
■ High-speed centrifuge
■ 2-Mercaptoethanol (Sigma)
■ 70% Ethanol
■ DNase I (Qiagen)
Method
1. The initial number of cells should not exceed 1 ¥ 107 cells and it recommended to start with
approximately 3 ¥ 106 to 4 ¥ 106 cellsa,b. 
2. Add 2-mercaptoethanol or ethanol to the relevant buffers following the manufacturer’s
instructions.
3. Add 350–600 mlc of lysis buffer to 3 ¥ 106 to 1 ¥ 107 cells. Vortex and pass the lysate at least
ﬁve times through a 20-gauge needle ﬁtted to an RNase-free syringe, which homogenizes the
cells. 
4. Apply the lysate to an AllPrep DNA spin column placed in a 2 ml collection tube. Genomic DNA
will bind to the DNA spin column.
5. Centrifuge for 1 min at ≥10 000 r.p.m. at room temperature.
6. Place the AllPrep DNA spin column in a new 2 ml collection tube and store at 4°C for later
DNA puriﬁcation. The ﬂow-through will contain RNA.
7. RNA and DNA can be puriﬁed from the ﬂow-through and spin column, respectively, following
the manufacturer’s instructions.
8. If possible, reverse transcribe the RNA immediatelyd.
9. Quantify the RNA and DNA using a spectrophotometere.
Notes
aIn human articular cartilage, cells only represent 3–5% of the tissue. Cells can be isolated by
sequential treatment with:
• Trypsin (10% in PBS) for 30 min at 37°C
• Hyaluronidase (1 mg/ml in PBS) for 15 min at 37°C
• Collagenase B (10 mg/ml, Roche) for 12–15 h
The cells can then be washed in PBS and the cell suspension ﬁltered through a sterile 70 mm sterile
cell strainer, followed by centrifugation for 5 min at 1700 r.p.m. The main steps in this procedure
are summarized in Fig. 3.
bIn practice, a conﬂuent T25 ﬂask provides just enough cells, whilst a conﬂuent T80 ﬂask is ample.
cThe volume of lysis buffer and wash buffer depends on the number of starting cells: for up to 
3 ¥ 106 cells use 350 ml of lysis buffer, and for up to 1 ¥ 107 cells use 600 ml of lysis buffer.
dIt is highly advisable to reverse transcribe RNA immediately into cDNA, which only takes a further
1.5 h. Alternatively, RNA can be frozen at –80°C. 
eQuantiﬁcation of RNA with the spectrophotometer often gives a low reading. This is because the
RNA spin column preferentially binds mRNA, whereas small ribosomal RNA ﬂows through. When
total RNA is extracted by the Trizol method, the majority of RNA is ribosomal, which can easily be
quantiﬁed. Using the column method, good PCR bands are often obtained even when the RNA
released from the spin column cannot be quantiﬁed.
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Although the bisulﬁte modiﬁcation method has been used more extensively for
determining methylation status, several groups have successfully used the MSRE
PCR method (see Protocols 3 and 4) (7–9). 
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Figure 3. Schematic ﬂow diagram of the steps in the simultaneous extraction of RNA
and genomic DNA from the same specimen.
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Restriction enzyme digest
Equipment and Reagents
■ Genomic DNA (5–10 ng/ml)
■ Thermal cycler with heated lida or water bath (37 or 65°C) 
■ Restriction enzyme(s)
■ Relevant buffer and 100¥ bovine serum albumin (BSA) if required (New England Biolabs or
similar)
■ PCR-grade DNase/RNAse-free water
■ PCR tubes, pipettes, and tips
Method
1. Check the concentration of supplied enzyme. For a 10 ml reaction, ~2–4 units are requiredb.
2. For each reaction, set upc:
■ 9 ml of extracted genomic DNA (5 ng/ml)
■ 1 ml of 10¥ buffer
■ 0.1 ml of 100¥ BSA (if required)
■ 0.2–2 ml of restriction enzyme, containing 2–4 units of activity
3. For each specimen, set up a parallel sample, omitting the enzyme. This will be the no-enzyme
control for the PCR.
4. Incubate at the recommended temperature for the enzyme (usually 37°C) for the
recommended time (usually overnight).
5. To denature the enzyme, heat at 65°C (some enzymes need 80°C or cooling at 4°C) for
10–20 min.
6. Enzyme-treated DNA may be stored for up to 1 week at 4°C, but it is best to carry out the PCR
immediately after enzyme digestion. 
Notes
aThe heated lid of a thermal cycler prevents condensation of the reaction mixture on the lid of the
tube, which may be a problem in a water bath or incubator.
bToo much enzyme or incubation for too long increases nonspeciﬁc digestion, whilst digestion will
not be complete when using too little enzyme or too short a time interval. Hence, it is essential to
perform preliminary studies for each enzyme, using universally methylated DNA (Chemicon
International, cat. no. S7821) or universally nonmethylated DNA. The latter can be obtained, using
the GenomiPhi v2 DNA ampliﬁcation kit (GE Healthcare Life Sciences). 
cIf several samples are to be treated with the same restriction enzyme, it may be useful to prepare
a ‘master mix’ of enzyme, buffer, and BSA.
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PCR
Equipment and Reagents
■ Digested DNA from Protocol 3
■ Platinum PCR SuperMix (Invitrogen) containing PCR buffer, MgCl2, and dNTPs
■ Oligonucleotides (10 mM)
■ Thermal cycler
■ 2% Agarose gel containing 10 ng/ml ethidium bromide
■ 6¥ Orange loading dye solution (Fermentas)
■ Equipment and reagents for agarose gel electrophoresis including 1¥ TBE agarose gel
running buffer (10.8 g/l Tris base; 5.5 g/l boric acid; 4 ml/l 0.5 M EDTA, pH 8.0, diluted from
a 10¥ stock; Sigma)
■ DNA size marker (100 bp ladder; Invitrogen)
■ UV light source
Method
1. Combine per 25 ml reaction (it is not necessary to have a 50 ml reaction mixture, as
recommended by the Invitrogen protocol):
■ 23 ml Platinum PCR SuperMix
■ 0.5 ml of each forward and reverse primer
■ 1 ml of DNAa
2. Mix brieﬂy by vortexing or pipetting. Centrifuge at 12 000 g g for 5–10 s to consolidate the
sample.
3. Amplify the DNA using the following PCR proﬁle:
■ 94°C for 2 min
■ 35 cycles of 94°C for 30 s, annealing using at a primer-dependent temperature for 30 s,
and 72°C for 1 min
■ 72ºC for 5 min
4. Analyze the PCR products by mixing 10 µl of the reaction mix with 1 µl of 6¥ orange loading
dye solution and resolving the sample by agarose gel electrophoresis alongside a DNA size
markerb.
Notes
aIt is important to PCR amplify the no-enzyme control DNA in order to assess the effect of
enzymatic digestion on the PCR. A negative control is also essential to determine any possible PCR
contamination.
bThe assessment of methylation status depends on the difference in intensity between the band
from enzyme-digested and that of the no-enzyme control. In an ideal specimen, a strong band is
present in the no-enzyme control, whilst no band is detectable in the corresponding enzyme-
digested sample.
288 ■ CHAPTER 17: PCR-BASED METHODS TO DETERMINE DNA METHYLATION STATUS
17-MX-PCR-ch17-ccp  20/3/07  17:42  Page 2882.6 Applications
In normal adult articular cartilage, the expression of proteases, such as MMP-13,
is silenced. However, in osteoarthritis, many cartilage cells abnormally produce the
enzyme, as has been shown by immunocytochemistry. Moreover, this abnormal
expression is stably transmitted to daughter cells. These observations suggest that
demethylation at some CpG sites in the promoter of the MMP-13 might have
‘unsilenced’ the gene and thus permitted abnormal expression of the protease. To
test this hypothesis, genomic DNA isolated directly from human articular cartilage
was subject to MRSE analysis for MMP-13. As can be seen in Fig. 4, all sites were
fully methylated in control cartilage, but loss of DNA methylation was found at
two CpG sites at –110 and –136 bp in the osteoarthritic specimen. When 16
osteoarthritis samples were compared with ten controls, demethylation at the
HpyCH4IV-cleavable site at –110 bp was present in the majority of osteoarthritis
samples (7), which suggests that this particular CpG site may be important in the
epigenetic ‘unsilencing’ of gene expression. 
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Figure 4. PCR of genomic DNA after treatment with MSREs.
Results are shown for the promoter region of MMP-13 in normal articular cartilage (top
row) compared with osteoarthritic cartilage (bottom row). All of the CpG sites in normal
articular cartilage are methylated, as indicated by the presence of PCR bands. Many of
these CpG sites are also methylated in the osteoarthritic sample (asterisks). However, loss
of methylation could be demonstrated in many osteoarthritic patients at the AvaI site at
–134 bp and the HpyCH4IV site at –110 bp (arrows). Reprinted with permission from (7).
In parallel experiments, reverse transcriptase PCR demonstrated clear induction
of MMP-13 in osteoarthritis samples with no expression in control (fracture neck
of femur, #NOF) samples (see Fig. 5). MRSE analysis of the same samples using the
HpyCH4IV-cleavable site at –110 bp identiﬁed clear PCR bands for the controls
(methylated, not susceptible to digestion; albeit reduced in intensity compared
with undigested samples), whilst the corresponding bands were either very weak
or absent in the osteoarthritis samples (unmethylated, susceptible to digestion).
Although this example demonstrates the correlation between methylation and
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methylation detection (see section 3). The reduced intensity of the PCR bands for
control samples could have been due to overdigestion or loss of methylation in
some cells. In the latter case, this loss of methylation obviously was not yet
sufﬁcient to induce gene transcription. In the ﬁrst osteoarthritis sample (OA1), a
faint band was still present, but was very weak compared with the no-enzyme
control. We would interpret this as absence of methylation. 
• A band is still present after enzyme digestion for the no-methylation
control 
As this negative control is universally unmethylated, one would expect an
absence of bands for all enzyme/primer combinations. If a PCR band is still
seen, then the conditions for enzyme digestion were not sufﬁcient to produce
complete digestion. Increase the enzyme concentration or the length of
digestion (but see overdigestion below). As PCR is involved, a reduction in the
number of cycles may also be beneﬁcial.
• Loss of band intensity is observed in the methylated control
As this control is universally methylated, one should not see any signiﬁcant
loss in band intensity after enzyme digestion. However, in practice we nearly
3. TROUBLESHOOTING
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Figure 5. Combined determination of mRNA expression (top) and DNA methylation
status (bottom).
Results are shown for two control samples, obtained from patients who had sustained a
fracture of the neck of the femur (#NOF), and two osteoarthritic patients (OA). MMP-13
(M13) expression was absent in the control samples, but present in the OA samples. After
digestion with HypCH4IV (hyp4) and PCR, a band was still present in the control samples,
but was either very weak or absent in the OA samples. GPDH, glyceraldehyde 3-
phosphate dehydrogenase; C, no-enzyme control for methylation status.
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degradation. If the PCR band is considerably reduced in intensity compared
with the no-enzyme control, then there is too much nonspeciﬁc degradation,
possibly following overdigestion. Reduce the enzyme concentration or the
length of digestion.
• In a specimen where loss of methylation would be expected, a weak band is
still visible
If conditions have been optimized using the positive and negative DNA
controls, the presence of a weak band in enzyme-treated samples may be due
in part to the nature of PCR and in part to the heterogeneity of the cells. If a
strong band is found in the no-enzyme control together with a weak band in
the enzyme-treated sample, a reduction in the number of PCR cycles may
eliminate the weak band, whilst still showing the presence of a band in the no-
enzyme control. 
• Heterogeneity of the cells with respect to the methylation status of a
particular CpG site
This is a problem in both the MSRE PCR and the bisulﬁte modiﬁcation
methods. In any one cell, a particular CpG site is either methylated or not
methylated, but this methylation status may vary within the cell population.
For example, assume that a particular gene is induced in a speciﬁc situation so
that 30% of the cells express this gene. Reverse transcriptase PCR will easily
demonstrate expression where there was none prior to induction. Let us
further assume that the induction was associated with loss of methylation at
a speciﬁc CpG site, i.e. this CpG site had become demethylated in 30% of the
cells. However, as this CpG site is still methylated in 70% of the cells, a strong
PCR band would be present. Thus, it would be impossible to demonstrate
changes in methylation status, even though these were present. To overcome
these difﬁculties, we would recommend developing real-time PCR assays to
measure the degree of methylation.
• No PCR band is visible in the no-enzyme control
If the total amount of genomic DNA is too low, no PCR band may be visible in
the no-enzyme control. In this case, either amplify for a further 5–10 cycles
(recommended if a very faint band is visible) or use the PCR product for a
further round of 30–35 cycles of PCR using the same primers. This is quite
successful for most primers, but nonspeciﬁc ampliﬁcation and additional
random bands can also occur. In this case, design nested primers for the
second round of PCR to amplify a region just inside the ﬁrst primer product.
This will usually eliminate the spurious additional bands.
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